查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1783712

全球羧甲基纤维素市场成长、规模和趋势分析—剂型展望、分销管道、地区、竞争策略和细分市场预测（至 2034 年）

Global Carglumic Acid Market Growth, Size, Trends Analysis - By Dosage Form, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 248 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年全球葡聚醣酸市场将达到 3.0994 亿人，复合年增长率为 7.69%。

卡谷氨酸由N-麸胺酸生成，可活化尿素循环中的第一个酶，从而帮助氨的排放和解毒。此药尤其适用于治疗丙酸血症和甲基丙二酸血症等罕见疾病，这些疾病属于体染色体隐性遗传，通常需要终生药物治疗才能维持正常健康。

阻碍因素：卡谷氨酸的使用受到原料采购成本高、产品加工所需资金增加、卡谷氨酸治疗相关副作用的限制。此外，研发成本的不断增加以及药物本身的高昂价格也推高了整体製造成本，导致消费者寻求替代品。

本报告调查了全球羧甲基纤维素钠市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、阻碍因素、机会与挑战分析

第五章：变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争态势

  • 製造地、销售区域、产品类型分布
  • 併购、合作、产品发布与合作

7. 全球羧甲基纤维素市场（以剂型）

  • 口溶锭
  • 分散片
  • 其他的

8. 全球氨基甲酸市场（依分销管道）

  • 医院药房
  • 零售药局
  • 网路药局

第九章：全球氨基甲酸市场

  • 市场规模和市场占有率

第 10 章全球氨基甲酸市场（按地区）

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十一章：公司简介

  • Apothecon Pharmaceuticals Pvt. Ltd
  • Recordati Rare Diseases Inc
  • Manus Aktteva Biopharma LLP
  • Dipharma Francis Srl
  • NURAY CHEMICALS
  • NOVITIUM PHARMA LLC
  • Suven Life Sciences Limited
  • Biophore India Pharmaceuticals Pvt Ltd
  • Rhyme Organics and Chemicals Ltd
  • Aktteva Biopharma LLP
  • 其他的

第十二章 结论

第十三章简称表

第 14 章参考链接

简介目录
Product Code: HLCA25177

Carglumic Acid Market Introduction and Overview

According to SPER market research, 'Global Carglumic Acid Market Size- By Dosage Form, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Carglumic Acid Market is predicted to reach 309.94 million by 2034 with a CAGR of 7.69%.

Carglumic acid is formed from N-acetyl glutamate and aids in ammonia elimination and detoxification by activating the first enzyme in the urea cycle. This medicine is particularly useful in the treatment of rare disorders such as propionic academia and methyl-malonic academia, which are autosomal recessive and frequently necessitate lifetime medical therapy to preserve normal health.

Restraints: The use of carglumic acid has been restricted by the high cost of acquiring raw materials, the increased capital required for processing the finished product, and certain negative consequences linked to carglumic acid treatments. Furthermore, rising research and development costs, combined with the high cost of medicine, have increased the cost of overall production, prompting customers to seek alternatives.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Dosage Form, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Apothecon Pharmaceuticals Pvt. Ltd, Recordati Rare Diseases Inc, Manus Aktteva Biopharma LLP, Dipharma Francis S.r.l, NURAY CHEMICALS, NOVITIUM PHARMA LLC, Suven Life Sciences Limited, Biophore India Pharmaceuticals Pvt Ltd, Rhyme Organics and Chemicals Ltd, Aktteva Biopharma LLP.

Global Carglumic Acid Market Segmentation:

By Dosage Form: Based on the Dosage Form, Global Carglumic Acid Market is segmented as; Orally Disintegrating Tablets, Dispersible Tablets.

By Distribution Channel: Based on the Distribution Channel, Global Carglumic Acid Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPER's internal database
    • 2.1.4.Premium insight from KOL's
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTER's Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Carglumic Acid Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Carglumic Acid Market

7.Global Carglumic Acid Market, By Dosage Form (USD Million) 2021-2034

  • 7.1.Orally Disintegrating Tablets
  • 7.2.Dispersible Tablets
  • 7.3.Others

8.Global Carglumic Acid Market, By Distribution Channel (USD Million) 2021-2034

  • 8.1.Hospital Pharmacies
  • 8.2.Retail Pharmacies
  • 8.3.Online Pharmacies

9.Global Carglumic Acid Market, (USD Million) 2021-2034

  • 9.1.Global Carglumic Acid Market Size and Market Share

10.Global Carglumic Acid Market, By Region, (USD Million) 2021-2034

  • 10.1.Asia-Pacific
    • 10.1.1.Australia
    • 10.1.2.China
    • 10.1.3.India
    • 10.1.4.Japan
    • 10.1.5.South Korea
    • 10.1.6.Rest of Asia-Pacific
  • 10.2.Europe
    • 10.2.1.France
    • 10.2.2.Germany
    • 10.2.3.Italy
    • 10.2.4.Spain
    • 10.2.5.United Kingdom
    • 10.2.6.Rest of Europe
  • 10.3.Middle East and Africa
    • 10.3.1.Kingdom of Saudi Arabia
    • 10.3.2.United Arab Emirates
    • 10.3.3.Qatar
    • 10.3.4.South Africa
    • 10.3.5.Egypt
    • 10.3.6.Morocco
    • 10.3.7.Nigeria
    • 10.3.8.Rest of Middle-East and Africa
  • 10.4.North America
    • 10.4.1.Canada
    • 10.4.2.Mexico
    • 10.4.3.United States
  • 10.5.Latin America
    • 10.5.1.Argentina
    • 10.5.2.Brazil
    • 10.5.3.Rest of Latin America

11.Company Profile

  • 11.1.Apothecon Pharmaceuticals Pvt. Ltd
    • 11.1.1.Company details
    • 11.1.2.Financial outlook
    • 11.1.3.Product summary
    • 11.1.4.Recent developments
  • 11.2.Recordati Rare Diseases Inc
    • 11.2.1.Company details
    • 11.2.2.Financial outlook
    • 11.2.3.Product summary
    • 11.2.4.Recent developments
  • 11.3.Manus Aktteva Biopharma LLP
    • 11.3.1.Company details
    • 11.3.2.Financial outlook
    • 11.3.3.Product summary
    • 11.3.4.Recent developments
  • 11.4.Dipharma Francis S.r.l
    • 11.4.1.Company details
    • 11.4.2.Financial outlook
    • 11.4.3.Product summary
    • 11.4.4.Recent developments
  • 11.5.NURAY CHEMICALS
    • 11.5.1.Company details
    • 11.5.2.Financial outlook
    • 11.5.3.Product summary
    • 11.5.4.Recent developments
  • 11.6.NOVITIUM PHARMA LLC
    • 11.6.1.Company details
    • 11.6.2.Financial outlook
    • 11.6.3.Product summary
    • 11.6.4.Recent developments
  • 11.7.Suven Life Sciences Limited
    • 11.7.1.Company details
    • 11.7.2.Financial outlook
    • 11.7.3.Product summary
    • 11.7.4.Recent developments
  • 11.8.Biophore India Pharmaceuticals Pvt Ltd
    • 11.8.1.Company details
    • 11.8.2.Financial outlook
    • 11.8.3.Product summary
    • 11.8.4.Recent developments
  • 11.9.Rhyme Organics and Chemicals Ltd
    • 11.9.1.Company details
    • 11.9.2.Financial outlook
    • 11.9.3.Product summary
    • 11.9.4.Recent developments
  • 11.10.Aktteva Biopharma LLP
    • 11.10.1.Company details
    • 11.10.2.Financial outlook
    • 11.10.3.Product summary
    • 11.10.4.Recent developments
  • 11.11.Others

12.Conclusion

13.List of Abbreviations

14.Reference Links